Proton pump inhibitor Co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil

Transplantation Proceedings

Volumn 42, Issue 10, 2010, Pages 4243-4246

  Doesch, A O ^a   Mueller, S ^a   Konstandin, M ^a   Celik, S ^a   Erbel, C ^a   Kristen, A ^a   Frankenstein, L ^a   Koch, A ^a   Ehlermann, P ^a   Zugck, C ^a   Katus, H A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; RAPAMYCIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG DOSE TITRATION; DRUG EXPOSURE; EVALUATION AND FOLLOW UP; EVENING DOSAGE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL;

AGED; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTON PUMP INHIBITORS;

EID: 78650470433     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.09.047     Document Type: Conference Paper

References (10)

1. J.A. Kobashigawa, and B.M. Meiser Review of major clinical trials with mycophenolate mofetil in cardiac transplantation Transplantation 80 2 Suppl 2005 S235
2. E.M. Eugui, S.J. Almquist, and C.D. Muller Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion Scand J Immunol 33 1991 161
3. A.C. Allison, and E.M. Eugui The design and development of an immunosuppressive drug, mycophenolate mofetil Springer Semin Immunopathol 14 1993 353
4. A.O. Dosch, P. Ehlermann, and A. Koch A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin Acontaining and cyclosporin Afree immunosuppressive regimens Clin Ther 28 2006 893
5. S. Kofler, M.A. Deutsch, and A.K. Bigdeli Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients J Heart Lung Transplant 28 2009 605
6. B. Diaz, F. Gonzalez Vilchez, and L. Almenar Gastrointestinal complications in heart transplant patients: MITOS study Transplant Proc 39 2007 2397
7. M. Vogl, G. Weigel, and G. Seebacher Evaluation of the EMIT mycophenolic acid assay from Dade Behring Ther Drug Monit 21 1999 638
8. H. Hosotsubo, S. Takahara, and R. Imamura Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay Ther Drug Monit 23 2001 669
9. L.M. Shaw, A. Nicholls, and M. Hale Therapeutic monitoring of mycophenolic acid A consensus panel report Clin Biochem 31 1998 317
10. S. Kofler, N. Shvets, and A.K. Bigdeli Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipientsa prospective case-controlled study Am J Transplant 9 2009 1650